Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models.
Blanca CucarullAnna TutusausMiguel SubíasMilica StefanovicTania Hernáez-AlsinaLoreto BoixMaría ReigPablo García de FrutosMontserrat MaríAnna ColellJordi BruixAlbert MoralesPublished in: Cancers (2020)
Regorafenib primes tumor cells to BH3-mimetic-induced cell death, allowing BCL-xL inhibition with A-1331852 or other strategies based on BCL-xL degradation to enhance regorafenib efficacy, offering a novel approach for HCC treatment, particularly for tumors with an elevated BCL-xL/MCL-1 ratio.